YOLFTbeta
21

Kyongbo Pharmaceutical Co Ltd

214390 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

4,950.00KRW+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close4,950.00
Open4,925.00
Day Range4,660.00 – 5,040.00
52-Week Range4,700.00 – 9,300.00
Volume19.10K
Market Cap130.77B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.92%
Beta0.34
50-Day Avg5,292.50
200-Day Avg5,846.85

About

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research and development of Clopidogrel cardiovascular drug, Imatinlb anticancer drug, Donepezil anti-psychotic drug, Entecavir for anti-virus and infectious disease, and Esomeprazole. It also exports its products. The company was formerly known as Kyongbo Chemical Co. Ltd. and changed its name to Kyongbo Pharmaceutical Co., Ltd in March 2002. Kyongbo Pharmaceutical Co., Ltd was founded in 1987 and is headquartered in Asan-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOTae-Young Kim
  • Employees0
  • Headquarters174, Sirok-ro, Asan-si, South Korea, Korea
  • Websitehttps://www.kbpharma.co.kr

Leadership

  • Tae-Young KimChief Executive Officer

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue169.78B178.03B186.73B191.66B201.34B191.71B215.29B170.66B196.26B216.36B238.56B264.10B
Growth (%)-+4.86%+4.88%+2.64%+5.05%-4.79%+12.30%-20.73%+15.00%+10.24%+10.26%+10.71%
Cost of Revenue119.98B129.48B142.62B137.04B152.08B150.99B162.82B135.30B151.85B153.28B149.28B161.80B
Gross Profit49.81B48.56B44.10B54.62B49.26B40.72B52.46B35.36B44.42B63.08B89.27B102.30B
Gross Margin29.34%27.27%23.62%28.50%24.47%21.24%24.37%20.72%22.63%29.15%37.42%38.74%
Operating Expense22.14B22.92B28.51B30.04B31.99B34.52B46.79B39.96B43.03B57.53B78.82B98.79B
Operating Income27.67B25.63B15.59B24.59B17.27B6.19B5.68B-4.60B1.39B5.54B10.45B3.52B
Operating Margin16.30%14.40%8.35%12.83%8.58%3.23%2.64%-2.69%0.71%2.56%4.38%1.33%
EBITDA38.47B34.91B26.97B36.76B29.72B20.04B18.27B8.16B13.12B17.27B21.60B17.94B
EBITDA Margin22.66%19.61%14.45%19.18%14.76%10.45%8.48%4.78%6.68%7.98%9.05%6.79%
Net Income8.64B26.11B12.71B17.96B13.12B5.29B9.40B-7.50B610.59M2.97B4.64B182.29M
Net Income Margin5.09%14.67%6.80%9.37%6.51%2.76%4.37%-4.39%0.31%1.37%1.94%0.07%
R&D1.25B1.87B1.48B765.40M769.78M1.42B6.24B5.05B3.08B3.65B12.17B18.16B
R&D as % of Total Revenue0.74%1.05%0.79%0.40%0.38%0.74%2.90%2.96%1.57%1.69%5.10%6.88%
Interest Expense1.08B877.67M960.10M1.00B888.66M1.30B1.31B1.18B1.67B3.40B4.29B4.29B
Interest Expense % of Total Revenue0.64%0.49%0.51%0.52%0.44%0.68%0.61%0.69%0.85%1.57%1.80%1.62%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets168.03B195.49B203.74B204.87B221.62B237.82B253.24B236.98B240.54B266.31B283.89B319.54B
Total Liabilities99.70B72.67B74.33B63.36B72.61B88.65B97.18B91.28B96.84B121.92B137.73B173.80B
Total Equity68.33B122.82B129.40B141.51B149.01B149.16B156.06B145.70B143.70B144.38B146.15B145.74B
Cash6.95B4.40B4.58B6.40B4.99B6.77B11.44B4.29B6.35B4.48B4.13B7.23B
Total Debt47.28B39.09B41.08B28.83B42.57B56.42B63.27B56.59B64.51B---
Net Debt40.33B34.69B36.50B22.42B37.59B49.65B51.83B52.30B58.16B68.75B85.19B118.09B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow16.04B4.24B25.33B25.81B-1.14B23.67B20.80B17.97B10.13B4.84B149.12M7.46B
Investing Cash Flow-18.46B-27.78B-20.16B-6.40B-8.19B-28.13B-19.68B-16.17B-14.88B---
Financing Cash Flow4.51B20.77B-4.82B-16.84B7.82B6.11B4.42B-9.22B6.59B---
Capital Expenditure19.28B27.26B19.68B7.40B8.19B23.25B12.44B18.32B13.18B10.88B13.18B41.61B
Free Cash Flow-3.24B-23.02B5.64B18.41B-9.33B421.97M8.36B-355.61M-3.06B-6.03B-13.03B-34.16B
Dividends Paid6.45B6.45B6.57B4.78B5.98B4.78B2.39B2.39B1.20B1.20B1.20B1.20B
FCF to OCF-20.19%-542.92%22.29%71.34%819.99%1.78%40.20%-1.98%-30.19%-124.53%-8735.41%-458.16%
Dividend Paid to FCF-199.33%-28.04%116.47%25.97%-64.04%1133.10%28.60%-672.29%-39.10%-19.81%-9.18%-3.50%

Earnings

Report DateJul 31, 2015Nov 4, 2015Feb 5, 2016Apr 29, 2016Jul 29, 2016Oct 31, 2016Feb 3, 2017Apr 24, 2017Jul 28, 2017Nov 2, 2017Feb 1, 2018Apr 27, 2018Jul 27, 2018Nov 2, 2018Jan 31, 2019Apr 26, 2019Jul 26, 2019Nov 14, 2019Feb 5, 2020Apr 29, 2020Jul 30, 2020Oct 30, 2020Feb 9, 2021May 17, 2021Jul 30, 2021Oct 29, 2021Jan 21, 2022Apr 29, 2022Jul 29, 2022Oct 28, 2022Jan 30, 2023Apr 28, 2023Jul 28, 2023Oct 26, 2023Jan 29, 2024Apr 26, 2024Aug 14, 2024Nov 14, 2024Mar 18, 2025May 15, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------------------------
EPS Actual262.54212.98432.00184.09153.7550.49143.15146.91190.85233.63180.00169.09159.3295.72124.5090.23146.3260.56-76.0384.00192.00103.0014.0864.00-58.00-190.00-129.116.68-42.572.0059.54-30.9538.1731.9885.2169.016.5545.2373.27-29.06-72.54126.82-18.10-22.16124.39
Surprise---------------------------------------------
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-After-hoursPre-marketPre-marketPre-marketPre-market--Pre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hours-Pre-marketPre-marketPre-marketPre-marketPre-market-----

Key Statistics & Ratios

Market Cap130.77B
Enterprise Value273.03B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.47
Price / Book0.88
Revenue (TTM)279.55B
Gross Profit (TTM)107.47B
EBITDA16.74B
Profit Margin1.81%
Operating Margin1.24%
Return on Equity3.49%
Return on Assets0.48%
Shares Outstanding23.91M
Shares Float9.15M
Beta0.34
Dividend Yield0.92%
Dividend Rate50.00
Payout Ratio23.70%

Dividends

20251×
50.00Dec 29, 2025
20241×
50.00Dec 27, 2024
20231×
50.00Dec 27, 2023
20221×
50.00Dec 28, 2022
20211×
50.00Dec 29, 2021
20201×
100.00Dec 29, 2020
20191×
100.00Dec 27, 2019
20181×
200.00Dec 27, 2018
20171×
250.00Dec 27, 2017
20161×
200.00Dec 28, 2016
20151×
275.00Dec 29, 2015